When annotating for pathogenicity, no differences were identified comparing HLBCs and HER2-positive carcinomas, whereas HLBCs showed significant differences with HER2-negative MCs, with more damaging mutations of the differentially mutated genes affecting HER2-negative disease (P < 0.01, Bonferroni correction of the chi-square test; Additional file 4: Fig. S2C; Additional file 8: Table S6). This evidence concerns the gene ERBB2 and carcinoma.